iwNHL 2018 | Non-hodgkin lymphoma advances in 2018
Steven Rosen, MD, from the City of Hope, Duarte, CA, discusses the remarkable quantity and quality of information on blood cancer therapeutics that has been collected and presented at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. Dr Rosen expresses how it seems that we are very nearly approaching a cure for certain hematological malignancies, with the introduction of CAR T-cell therapy, bispecific antibodies and targeted therapies; all of which are producing promising results in clinical trials.
Transcript (edited for clarity)
I would say of all the iwNHL meetings, 2018 has been the best. It’s quite remarkable how much information was gained in just a one year period of time and the advances we’re seeing in therapeutics: in particular, CAR-T cell therapy, therapy using the bi-specific antibodies, also some of the pathway inhibitors: all very effective in inducing remissions, well-tolerated treatments.
There were also presentations about antibodies directing cytotoxic therapies that are inducing durable responses...
I would say of all the iwNHL meetings, 2018 has been the best. It’s quite remarkable how much information was gained in just a one year period of time and the advances we’re seeing in therapeutics: in particular, CAR-T cell therapy, therapy using the bi-specific antibodies, also some of the pathway inhibitors: all very effective in inducing remissions, well-tolerated treatments.
There were also presentations about antibodies directing cytotoxic therapies that are inducing durable responses. It feels like we’re on the precipice of really conquering a number of these diseases where historically we made an impact, but by the public’s perception not particularly dramatic.
Read more...
